EndoResFellow said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 82 95 >60…
Second this.
EndoResFellow said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 82 95 >60…
Second this.
Dr.PulmRoch said:GFR trending upward on renal function — encouraging for those with mild CKD concerns: Baseline eGFR: 71 → Month 6: 83 → Month 12: 91 The FLOW trial…
Can confirm. Same sequence, different timescale. Posting only so the count is not one.
Dr.PulmRoch said:GFR trending upward on renal function — encouraging for those with mild CKD concerns: Baseline eGFR: 71 → Month 6: 83 → Month 12: 91 The FLOW trial…
Adding the part of the answer the thread has not reached. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.
That is the short version; the long version is somebody else's post.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.
Correct me if the detail matters more than I have assumed.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.